Neuronetics (NASDAQ:STIM) Releases Earnings Results, Misses Expectations By $0.02 EPS

Neuronetics (NASDAQ:STIM) released its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Zacks reports. Neuronetics had a negative net margin of 43.47% and a negative return on equity of 156.36%. The company had revenue of $37.30 million during the quarter, compared to the consensus estimate of $37.85 million. Neuronetics updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Neuronetics Stock Down 4.5%

Shares of STIM stock traded down $0.13 during midday trading on Wednesday, reaching $2.74. 2,476,848 shares of the stock were exchanged, compared to its average volume of 1,264,228. Neuronetics has a 1 year low of $0.52 and a 1 year high of $5.92. The company’s 50 day moving average is $2.97 and its two-hundred day moving average is $3.59. The company has a current ratio of 2.02, a quick ratio of 1.84 and a debt-to-equity ratio of 1.76. The firm has a market cap of $181.18 million, a PE ratio of -2.42 and a beta of 1.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bridgeway Capital Management LLC grew its holdings in shares of Neuronetics by 55.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 70,205 shares of the company’s stock worth $245,000 after acquiring an additional 25,000 shares during the period. Balyasny Asset Management L.P. grew its stake in shares of Neuronetics by 6.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,509,099 shares of the company’s stock worth $5,267,000 after buying an additional 92,048 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Neuronetics in the 2nd quarter worth approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Neuronetics in the 2nd quarter worth approximately $69,000. Finally, Jump Financial LLC purchased a new stake in shares of Neuronetics in the 2nd quarter worth approximately $133,000. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on STIM shares. Canaccord Genuity Group lowered their target price on Neuronetics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.00.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.